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Summary In the search for effective chemotherapy regimens which can be used in multimodality treatment
programmes for patients with cancer of the oesophagus, we conducted a phase II trial to determine the activity
and toxicity of the combination of cisplatin and etoposide in patients with advanced squamous cell carcinoma
of the oesophagus. Seventy-three consecutive patients with unresectable or metastatic squamous cell carcinoma
of the thoracic oesophagus were treated with cisplatin 80 mg m-2 by 4 h infusion on day 1, etoposide 100 mg
(fixed dose) by 2 h infusion on day 1 and 2, and etoposide 200 mg m-2 orally on day 3 and 5. Courses were
repeated every 4 weeks, for a maximum of six courses. The oral dosages of etoposide were modified
individually until a significant degree ofmyelosuppression was reached. Of 65 evaluable patients, five complete
responses (CRs) and 26 partial responses (PRs) were seen, for an overall response rate of48% (95% confidence
interval 35-60%). Median time to progression was 7 months (range 3-72+months). There were two toxic
deaths (neutropenic sepsis). The response rate equals that of other cisplatin-based regimens. Its toxicity profile
allows addition of a third active drug such as 5-fluorouracil.
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Cancer of the oesophagus is an uncommon disease in western
countries. In contrast, the disease is among the most
frequently occurring malignancies in China, Japan, Asia
and South Africa. The age-adjusted mortality (3.4 persons
per 100 000) in the USA is nearly similar to the incidence: 3.9
persons per 100 000 (Roth et al., 1993). The mortality/
incidence ratio in the Netherlands is 1.07 for males and 0.99
for females, with an incidence of approximately 900 in 1990
and a male/female ratio of 2.5 (Visser et al., 1990). Most
patients are in their fifth to seventh decade of life. A long-
standing history of cigarette abuse and heavy alcohol intake
is strongly associated with the development of oesophageal
cancer, in particular with oesophageal squamous cell
carcinoma (ESCC). Although approximately half of the
patients present with localised disease, many of them will
have recurrences of metastatic disease despite aggressive local
treatment; the 5-year survival rate after radical resection is
only 10-15% (Muller et al., 1990). Obviously, there is a need
for effective systemic treatment. In reviews on single-agent
activity with cisplatin, 5-FU, bleomycin and mitomycin, the
response rate appears to be 15-20%, with a short duration
of response (3 months) (Roth et al., 1993). Etoposide showed
promising activity in ESCC in a phase I study, although a
phase II study with a low-dose schedule in pretreated patients
could not confirm these early results (Radice et al., 1979;
Coonley et al., 1983).
However, with a higher dose in non-pretreated metastatic
patients, considerable activity was documented (Harstrick et
al., 1992). Based on these data and our previously reported
experience that the combination of cisplatin and etoposide is
safe and effective in non-small-cell lung cancer (Splinter et al.,
1986), we have performed a phase II study with the
combination of these two drugs in patients with advanced
and/or metastatic squamous cell carcinoma of the oesopha-
gus.
Patients and methods
Patient selection
All patients who entered the study were required to have
inoperable ormetastatic histologically proven squamous cell or
undifferentiated non-small-cell cancer of the oesophagus.
Further eligibility criteria were age <75 years, performance
status WHO 0-2, a life expectancy of more than 3 months, a
reasonablefoodpassage,bidimensionallymeasurabledisease(or
evaluable disease ifthe primary tumour was the only indicator
lesion), WBC count >3 x I01 I1-, platelets >100 x10911-,
creatinine clearance >60 ml min-'. Prior chemotherapy was
notallowed.Patientswithovertbrainmetastases or anirradiated
primary tumour as the sole evaluable lesion were excluded. All
patients gave informed consent. The protocol was approved by
the Dutch Cancer Society.
Treatment
The intravenous (i.v.) treatment consisted of prehydration
with 1500 ml of saline/glucose (0.45%/2.5%) and 4 g of
magnesium sulphate over 14 h, followed by 100 mg (fixed
dose) etoposide dissolved in 500 ml 0.9% saline given over
2 h (day 1). Cisplatin (80 mg m-2) dissolved in 1000 ml 0.9%
saline was then administered over 4 h, followed by post-
hydration with 3500 ml saline/glucose over 24 h. During this
post-hydration period another 100 mg (fixed dose) of
etoposide dissolved in 500 ml 0.9% saline was given over
2 h, 24 h after the first dose of etoposide (day 2). After this
i.v. treatment, patients were discharged. Oral treatment
consisted of etoposide (capsules of 50 mg),
200 mg m-2 day-' on days 3 and 5, in three equal parts on
each day (at 10 am, 2 pm and 6 pm). In case of stenosis with
difficulty in swallowing, the content of the capsules was
dissolved in lemonade.
In case the WBC nadir remained above 2 x 109 l' and/or
the platelet nadir above 100 x 109 1-', the oral doses of
etoposide were increased until a significant nadir (WBC 1.0-
2.0 x 109 1'-l and/or platelets 25 - 100 x 109 1'- ) was reached.
This was done in order to counterbalance possible differences
in bioavailability of oral etoposide. In case of WBC nadir
<1.0 x 109 1-' and/or platelet nadir <25 x 10 1l-' a 25%
dose reduction of oral etoposide was carried out in the next
and subsequent courses.
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and/or platelets <100 x 10 I-1 on day 1 of the next planned
course. If after 2 weeks of delay WBC and/or platelets had
not recovered, patients went off treatment, but were followed
for time to progression and survival. No colony-stimulating
factors were used in this study.
In case of severe neurotoxicity (WHO grade >3) or renal
insufficiency (WHO >2), treatment was stopped perma-
nently. Routine anti-emetic support consisted of 10 mg
dexamethasone before and after administration of cisplatin
in combination with domperidon and lorazepam orally.
Sometimes 5-hydroxytryptamine receptor antagonists were
administered; these drugs were not yet routinely available in
the study period. Courses were repeated every 4 weeks until
progression, or up to a maximum of six courses.
Efficacy and toxicity
Response evaluation was done according to standard WHO
criteria (WHO, 1979). Complete response required complete
disappearance of all known tumour for at least 4 weeks,
including negative biopsies taken at endoscopy from previous
tumour sites. Partial response required a >50% reduction of
the product of the perpendicular diameters of all measurable
lesions, or a regression of more than 50% of the tumour
volume ifthe primary tumour in the oesophagus was the only
evaluable parameter, for at least 4 weeks (Agha et al., 1986).
Stable disease required a <50% reduction or <25% increase
in the size of indicator lesions. Progressive disease was
defined as a >25% increase in the size of tumour lesions or
the appearance of a new lesion. Time to progression and
survival were calculated from the first day of treatment.
Patients were evaluated for response after two courses of
chemotherapy or earlier if treatment was stopped owing to
severe toxicity. Evaluation of tumour response was done after
every second course. If progression of disease was evident
after one course, the patient was classified as having early
progressive disease. Toxicity was evaluated according to
standard WHO criteria at the day of retreatment (WHO,
1979).
Results
Patients
Between July 1985 and October 1991, 73 patients entered the
study. Patient characteristics are listed in Table I. At the time
of diagnosis, 60 patients had metastatic disease with the
primary tumour in situ, and three patients had non-resectable
primary tumours only. Ten patients had developed distant
metastases at a median time of 10.5 months (range 3-81
months) after local treatment [oesophageal resection (n=3),
radiotherapy alone (n=2), radiotherapy followed by oeso-
phageal resection (n=5)]. Two patients were not evaluable
for response and toxicity because of treatment refusal and
loss to follow-up after the first course for other than tumour-
or treatment-related reasons. Six patients were not evaluable
for response because of tumour-related complications [lethal
haematemesis in the presence of normal WBC and platelets
after the first course (n = 1), formation of fistulas between the
primary tumour and trachea and pleura respectively after the
first course with no change of disease (n =2), toxic death, i.e.
neutropenic sepsis before the first response evaluation (n =2),
or WHO grade 3 neurotoxicity after the first course (n= 1)].
Therefore, 71 patients were evaluable for toxicity and 65
patients for response.
Response
Table II shows the tumour response in 65 evaluable patients.
The overall response rate was 48% [95% confidence interval
(CI) 35-60%], including five CRs (8%) and 26 PRs (40%).
All patients with a CR had measurable tumour lesions and
three of them had a primary tumour in situ which also
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Table I Patient charactristics (n = 73)
Male
Female
Age (years)
Median
Range
WHO performance status
0
1°
2
Weight loss (%)
Unknown
0
1-5
6-10
10-20
>20
Tumour sites
Lymph nodes
Supraclavicular
Mediastinal
Coeliac
Oesophagus
Stomach
Pleura
Lung
Liver
Peritoneum
Kidney
Adrenal gland
Bone
Skin
Histological type
Squamous cell carcinoma
Undifferentiated large cell
carcinoma
Number of organ sites
1
2
-3
Prior treatment (n = 26)
Radiotherapy
Surgical resection
Radiotherapy and surgical resection
Celestin tube
53
20
60
41 -76
2
50
21
3
14
20
28
7
72
39
10
3
3
2
5
17
2
1
1
1
70
3
45
16
12
5
3
5
13
Table II Response evaluation (n = 65)
Response Patients %
Complete response 5 8
Primary and lymph nodes 4
Partial response 26 40
Primary and lymph nodes 5
Lymph nodes 16
Liver and lung 5
Stable disease 22 34
Progressive disease 9 14
Early progressive disease 3 4
disappeared. Of the 26 PRs, 23 patients had measurable
metastases; three had a primary tumour only which was
evaluated by endoscopy. In 23 of 31 responding patients, a
>50% tumour regression was observed after the first two
cycles. If one includes the patients in an 'intent-to-treat'
analysis, two toxic deaths and one early death should be
considered treatment failures, whereas one additional patient
achieved a CR, and two had stable disease (SD). In that case,
the overall response rate is 32 out of 71 patients (45%; 95%
CI 33-57%), including six CRs (8%). The median time to
progression in 17 responding patients (13 PRs, four CRs),
who did not receive additional treatment after chemotherapy,
was 6.9 months (range 3-72 +months). In 11 respondingCisplatin and etoposide in oesophageal cancer
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patients (10 PRs and one CR), who were treated with
radiotherapy (n=9, oesophagus and supraclavicular regions)
or surgery (n=2, transhiatal oesophagus resection) after
chemotherapy, the median time to progression was 11
months (range 5- 18 months). In three patients time to
progression could not be assessed.
Toxicity
Atotalnumberof252 courses wasgiven to 71 patientsevaluable
for toxicity (median 4 courses, range 1-6 courses). Treatment
was discontinued after six courses, according to the protocol
(n = 18); in case of no further regression after two subsequent
cycles of chemotherapy (n = 14); and in case of progressive
disease (n =20). In one patient chemotherapy was discontinued
for other than tumour- or treatment-related reasons.
There were two toxic deaths (3%) owing to neutropenic
sepsis. Three other patients died suddenly during treatment
because of hypovolaemic shock owing to massive upper
digestive tract bleeding with normal platelet counts. Autopsy
was not permitted in any of these three patients.
Seven patients discontinued treatment without evidence of
progressive disease because of intractable vomiting (n = 1),
neurotoxicity grade 3 and/or renal toxicity grade 3 (n =3), or
deterioration of general condition after five courses (n = 3).
Other reasons for discontinuation were pneumonia, perfora-
tion caused by a tube insertion and oesophageal -tracheal or
-bronchial fistulas. Fourteen cycles (5%) had to be
postponed (median number of days, 8.5); eight cycles (3%)
because of cytopenia, three cycles because of a recent
infection period and three cycles because of moderate
cardiac insufficiency in two patients. The oral dose of
etoposide could be escalated in 58 cycles and had to be
reduced in 36 cycles.
Table III shows haematological toxicity. Severe (WHO
grade 3 and 4) leucopenia and thrombopenia were not
encountered after the second course any more because of
dose modifications of orally given etoposide in subsequent
courses as stated in the protocol. Non-haematological
Table III Haematological toxicity
0 1 2 3 4 3+4(%)
WHO (71 patients)
Haemoglobin 17 21 30 3 0 4.2
WBC 11 10 22 19 9 39.4
Platelets 38 8 8 12 5 23.9
WHO (218 cycles)
Haemoglobin 93 85 38 3 0 1.4
WBC 57 45 71 36 9 20.6
Platelets 144 17 25 23 7 13.9
toxicity data are listed in Table IV. 5-HT3 receptor blockers
were rarely given throughout the study period which
probably explains grade 3 and 4 nausea and vomiting in
38% of the patients and 20% of the cycles. Alopecia was
common. Diarrhoea was infrequent. Two periods of grade 4
infection and leucopenia occurred: both patients died of
pneumonia owing to aspiration. All periods of grade 3
infection were related to the lungs. In half of the periods of
grade 2 infection, no focus could be determined; other
periods were related to the lungs (n=4) and the urogenital
tract (n=2). One patient with long-standing alcohol abuse
experienced severe neuropathy (WHO 3) after the first course.
In half of the patients mild to moderate increases in serum
creatinine were seen.
Survival
All patients, except one, have died. This patient with a
primary tumour in situ and pathologically confirmed
metastases in the left cervical region, reached CR after four
cycles. He is alive and well, without any evidence of disease
after >72 months.
The median survival time in all patients (n =73) from the
start of treatment was 8.5 months (range 0.5-72+months).
Nineteen patients (26%) survived for more than 1 year. The
median survival time in responding patients without
consolidation treatment (radiotherapy, surgery) was 10
months (range 3.0-72+months), compared with a median
of 5.5 months (range 1.0-26.4 months) in non-responding
patients.
Discussion
Notwithstanding a substantial decrease in post-operative
mortality after oesophageal resection in the last 15 years,
long-term survival rates in patients with oesophageal cancer
are still very low as a consequence of the systemic nature of
this disease. As a result of the relative rarity and the poor
performance status of most patients, data on systemic
treatment in oesophageal cancer are scarce. No controlled
trials of chemotherapy vs best supportive care have been
reported.
Cisplatin as a single agent in ESCC was reported for the
first time in 1980 (Davis et al., 1980; Ravry et al., 1985;
Engstrom et al., 1983). The Southwest Oncology Group
(SWOG) reported an overall response rate of 26% among 35
evaluable patients (6 PRs and 3 CRs) with a regimen of
50 mg m-2 cisplatin on day 1 and 8 (Panetierre et al., 1984).
The median response duration in these trials was 3-4
months. Despite the limited value of compiled trial data, an
overall response rate of 25% with single-agent cisplatin in
Table IV Non-haematological toxicity
WHO grade
0 1 2 3 4
Toxicity (no. of patients)
Nausea/vomiting (71) 6 13 25 26 1
Alopecia (66) 2 1 19 38 6
Diarrhoea (71) 61 3 7 0 0
Infection (71) 55 2 6 6 2
Peripheral neuropathy (71) 67 2 1 1 0
Renal (71) 31 36 4 0 0
Toxicity (no. of cycles)
Nausea/vomiting (243) 35 59 102 46 1
Alopecia (225) 7 5 90 113 10
Diarrhoea (250) 237 5 8 0 0
Infection (250) 228 2 12 6 2
Peripheral neuropathy (250) 243 2 4 1 0
Renal (243) 173 66 4 0 0Cisplati and etopside in oesophageal cancer
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oesophageal cancer seems credible (Ajani. 1994). The dose-
limiting toxicity is neurotoxicity (especially in patients with
high alcohol intake) and ototoxicity.
Because of encouraging results of etoposide in patients
with ESCC in phase I studies, Harstrick et al. (1992) studied
a dose regimen of 200 mg m- i.v. on 3 consecutive days in
26 patients, which yielded five partial responses with a
duration of 3, 4, 5. 5 and 8 months. Half of the patients
experienced grade 3 leucopenia as major toxicity. No severe
organ toxicities were recorded. Higher fractionations of
etoposide could lead to higher activity, as has been shown
by several authors (Clark. 1992). Other single agents, such as
bleomycin, 5-fluorouracil, mitomycin, methotrexate and
vindesine, are effective in only 15-20% of the cases. with
no substantial survival benefit (Roth et al., 1993. Recently.
some new agents have been tested: vinorelbine, carboplatin,
iproplatin and paclitaxel. With vinorelbine in non-pretreated
patients with squamous cell carcinoma, 6 24 obtained a
partial remission; these results have not yet been confirmed
(Conroy et al.. 1993). Negative results have been reported
with the platinum analogues. carboplatin and iproplatin
(Stemnberg et al., 1985; Steel et al.. 1988; Mannell. 1989;
Cappelaere et al.. 1993). Preliminary results from a phase II
trial with paclitaxel have shown interesting activity: an
overall response rate of 31% (95% CI 17-45%, no CR)
with a median response duration of 4 months (range 1-
11 +months) was recorded (Ajani et al., 1994). In the clinic.
cisplatin appears to be an excellent drug for combination
chemotherapy, especially with etoposide or teniposide.
because of few overlapping toxicities. In addition, dose-
dependent activity and even synergy has been demonstrated
in animal models (Achterrath et al.. 1982; Chen et al.. 1984;
Ross et al.. 1984: Long et al.. 1985).
Until now, more than 15 combination schemes for
oesophageal cancer have been reported. Two schedules have
been studied with adequate numbers ofpatients: cisplatin and
5-fluorouracil and cisplatin with vindesine and bleomycin.
This latter combination has induced substantial pulmonary
toxicity. although a response rate of approximately 50% in
several studies was reported (Kelsen et al.. 1983. 1990:
Dinwoodie et al.. 1986. Response rates of cisplatin with 5-
fluorouracil and or leucovonrn treatment are in the 35-50%
range. sometimes even higher (Bleiberg et al.. 1991: De Besi
et al., 1986; Iizuka et al.. 1991: Hayashi et al.. 1992:
Spielmann et al., 1993).
In this study. we applied the same dosages and schedule of
cisplatim and etoposide. as we have previously reported in
patients with non-small-cell lung cancer (Splinter et al.. 1986).
The rationale of an extended administration of etoposide
over several days has been justified by several authors in the
light of the schedule-dependent cytotoxicity of this drug
(Cavalli et al., 1978; Slevin et al.. 1989). In addition, this
regimen reduces the length of hospital stay to a maximum of
3 days. The toxicity turned out to be manageable w-tih two
toxic deaths (3%) and seven other patients (10%) who
refused continuation because of side-effects. Dose escalations
of etoposide could be applied more often than dose
reductions were required. The dominant side-effects of
nausea and vomiting (WHO grade 2 and 3. 72%) observed
in our study, can presently be reduced or even eliminated
using 5-HT3 receptor antagonists.
Adenocarcinoma of the oesophagus is being seen
increasingly frequently among Western European and
American patients. In our hands however. this regimen
showed no activity in patients with this histological subtype.
as previously reported (Kok et al.. 1988).
Our results seem to equal those of other cisplatin-based
regimens. The favourable toxicity profile of our regimen has
led us to perform a phase II trial of the combination of
cisplatin. etoposide and a third active drug. 5-fluorouracil.
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